These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 34942275)

  • 41. Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis.
    Matthews PM; Datta G
    Expert Opin Drug Discov; 2015 May; 10(5):557-70. PubMed ID: 25843125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trials and tribulations: oncological antibody imaging comes to the fore.
    Zuckier LS; DeNardo GL
    Semin Nucl Med; 1997 Jan; 27(1):10-29. PubMed ID: 9122720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA approves 18F-florbetapir PET agent.
    J Nucl Med; 2012 Jun; 53(6):15N. PubMed ID: 22661593
    [No Abstract]   [Full Text] [Related]  

  • 44. Proceedings: PET Drugs-A Workshop on Inspections Management and Regulatory Considerations.
    Bunning S; Ignace C; Mattmuller S; Schwarz SW; Scott PJH; VanBrocklin HF; Zigler SS;
    J Nucl Med; 2022 Jul; 63(7):1117-1123. PubMed ID: 35058318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radioactive synthesis of tau PET imaging agent
    Zhang W; Xu S; Yu H; Li X; Jin Z; Li Y; He Z
    Ann Nucl Med; 2021 Feb; 35(2):139-147. PubMed ID: 33460010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDA Approves New
    J Nucl Med; 2022 Feb; 63(2):26N. PubMed ID: 35101932
    [No Abstract]   [Full Text] [Related]  

  • 47. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.
    Boswell CA; Brechbiel MW
    Nucl Med Biol; 2007 Oct; 34(7):757-78. PubMed ID: 17921028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toward molecular imaging-driven drug development in oncology.
    de Vries EG; Oude Munnink TH; van Vugt MA; Nagengast WB
    Cancer Discov; 2011 Jun; 1(1):25-8. PubMed ID: 22586317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Utility of positron emission tomography for drug development for heart failure.
    Papadimitriou L; Smith-Jones PM; Sarwar CM; Marti CN; Yaddanapudi K; Skopicki HA; Gheorghiade M; Parsey R; Butler J
    Am Heart J; 2016 May; 175():142-52. PubMed ID: 27179733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Systematic Assessment of US Food and Drug Administration Dosing Recommendations For Drug Development Programs Amenable to Response-Guided Titration.
    Wang L; Maxfield K; Guinn D; Madabushi R; Zineh I; Schuck RN
    Clin Pharmacol Ther; 2021 Jan; 109(1):123-130. PubMed ID: 33022770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy: Commercial Parenteral Nutrition Formulas Versus Compounded Arginine/Lysine.
    Al-Toubah T; Sikaria D; Jesurajan J; Bottiglieri S; Smith J; Pellé E; Hutchinson T; Strosberg J; El-Haddad G
    Pancreas; 2021 Apr; 50(4):513-515. PubMed ID: 33939662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
    Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
    Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Instrumentation and radiopharmaceutical validation.
    Zigler SS
    Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Milestone: Approval of CEUS for Diagnostic Liver Imaging in Adults and Children in the USA.
    Seitz K; Strobel D
    Ultraschall Med; 2016 Jun; 37(3):229-32. PubMed ID: 27276056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain Tau Imaging: Food and Drug Administration Approval of
    Mattay VS; Fotenos AF; Ganley CJ; Marzella L
    J Nucl Med; 2020 Oct; 61(10):1411-1412. PubMed ID: 32753388
    [No Abstract]   [Full Text] [Related]  

  • 57.
    Carlucci G; Ippisch R; Slavik R; Mishoe A; Blecha J; Zhu S
    J Nucl Med; 2021 Feb; 62(2):149-155. PubMed ID: 33443068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Food and drug administration approval process for dermatology drugs in the United States.
    Boozalis E; Semenov YR; Kwatra SG
    J Dermatolog Treat; 2018 Sep; 29(6):536-538. PubMed ID: 29304565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The application of positron emission tomography (PET) imaging in CNS drug development.
    Suridjan I; Comley RA; Rabiner EA
    Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis, pharmacology and preclinical evaluation of
    Chen Z; Mori W; Zhang X; Yamasaki T; Dunn PJ; Zhang G; Fu H; Shao T; Zhang Y; Hatori A; Ma L; Fujinaga M; Xie L; Deng X; Li H; Yu Q; Rong J; Josephson L; Ma JA; Shao Y; Tomita S; Zhang MR; Liang SH
    Eur J Med Chem; 2018 Sep; 157():898-908. PubMed ID: 30145376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.